ARTICLE | Finance
Few Cinderellas this time
Big biotechs suffer least in 3Q11, as smaller cap groups drop as much as 25%
October 3, 2011 7:00 AM UTC
Big caps suffered the least in a very ugly quarter. But that's not saying much: biotechs with market caps of more than $5 billion were still down 10% as a group in 3Q, while other market cap groups shed 18-26%.
The best performer among the big caps was Alexion Pharmaceuticals Inc., which gained 36%. It was the only big cap that gained double digits...